Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B99 phase 2 platform study in first-line extensive-stage small cell lung cancer
MOH_2021-06-23_010076Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab, mk-4830, omaveloxolone and lenvatinib in small cell lung cancer (SCLC) (3 arms), sponsored by Merck & Co. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2021-06-23_010076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-23_010076.